Deutsche Bank AG Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Deutsche Bank AG acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 518,409 shares of the biopharmaceutical company’s stock, valued at approximately $323,249,000.

Several other large investors have also recently added to or reduced their stakes in the business. Perigon Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $4,467,000. Commerzbank Aktiengesellschaft FI acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $316,000. Trust Co. of Vermont acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $29,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $160,530,000. Finally, OneDigital Investment Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $392,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 0.3%

Shares of Regeneron Pharmaceuticals stock opened at $805.93 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market capitalization of $82.98 billion, a P/E ratio of 19.92, a PEG ratio of 1.37 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The company’s fifty day moving average is $679.69 and its two-hundred day moving average is $714.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the prior year, the company earned $12.81 earnings per share. The business’s revenue was up 16.7% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on REGN. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Truist Financial increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $801.70.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.